Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Original Article
R.J. Motzer, N.M. Tannir, D.F. McDermott, O.A. Frontera, B. Melichar, T.K. Choueiri, E.R. Plimack, P. Barthélémy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C.K. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M.-O. Grimm, S. Bracarda, C.H. Barrios, Y. Tomita, D. Castellano, B.I. Rini, A.C. Chen, S. Mekan, M.B. McHenry, M. Wind-Rotolo, J. Doan, P. Sharma, H.J. Hammers, and B. Escudier
N Engl J Med 2018;378:1277-1290
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Sunday, April 5, 2020 - 11:59pm.